Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBT (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed EBT for 13 consecutive years, with -$109.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 2.01% year-over-year to -$109.2 million, compared with a TTM value of -$415.7 million through Dec 2025, down 158.29%, and an annual FY2025 reading of -$413.8 million, down 157.63% over the prior year.
  • EBT was -$109.2 million for Q4 2025 at Agios Pharmaceuticals, down from -$103.4 million in the prior quarter.
  • Across five years, EBT topped out at $1.0 billion in Q3 2024 and bottomed at -$112.5 million in Q2 2025.
  • Average EBT over 5 years is -$39.6 million, with a median of -$92.0 million recorded in 2022.
  • The sharpest move saw EBT soared 1196.14% in 2024, then plummeted 110.33% in 2025.
  • Year by year, EBT stood at -$98.6 million in 2021, then increased by 5.98% to -$92.7 million in 2022, then dropped by 5.36% to -$97.7 million in 2023, then fell by 9.59% to -$107.0 million in 2024, then decreased by 2.01% to -$109.2 million in 2025.
  • Business Quant data shows EBT for AGIO at -$109.2 million in Q4 2025, -$103.4 million in Q3 2025, and -$112.5 million in Q2 2025.